National Peroxide FY26 turnaround: profit, ₹7 dividend

National Peroxide returns to profit in FY2026

National Peroxide Ltd reported a sharp turnaround in FY2026, moving from a loss in FY2025 to a profitable year on the back of improved quarterly performance. The company disclosed FY2026 total income of ₹295.68 crore and profit after tax (PAT) of ₹11.04 crore. In FY2025, it had posted a PAT loss of ₹2.25 crore. Earnings per share (EPS) for FY2026 stood at ₹19.20 (basic and diluted), compared with a loss per share of ₹3.91 in FY2025. The FY2026 numbers were accompanied by a proposed final dividend, signalling a reset after a weak FY2025.

Board meeting on April 30, 2026: audited results and dividend

National Peroxide said its Board of Directors would meet on Thursday, April 30, 2026 to consider and approve audited financial results for the quarter and financial year ended March 31, 2026. The same meeting was also set to consider recommending a dividend for the year ended March 31, 2026, if applicable. Following the meeting, the board recommended a final dividend of ₹7 per equity share for FY2026. The company described this as a 70% dividend, subject to shareholder approval at the upcoming AGM. The disclosures were made in the context of corporate actions and regulatory filings.

Q3 FY2026 results: revenue growth and profit turnaround

For Q3 FY2026, National Peroxide reported revenue from operations of ₹69.09 crore, up 11.15% from ₹62.16 crore in Q3 FY2025. Total income for the quarter was ₹69.99 crore compared with ₹62.52 crore a year earlier. The company reported PAT of ₹1.83 crore in Q3 FY2026 versus a loss of ₹1.52 crore in Q3 FY2025. Basic EPS for the quarter came in at ₹3.19, compared to a loss per share of ₹2.64 in the prior-year quarter. The board approved these unaudited Q3 results at its meeting held on February 5, 2026.

Nine-month FY2026 performance: revenue down, profit lower YoY

For the nine months ended December 31, 2025, National Peroxide reported revenue from operations of ₹204.03 crore, compared with ₹213.17 crore in the corresponding period of the previous year. Total income for the nine-month period was ₹208.62 crore versus ₹217.65 crore in the previous year. PAT for the nine months stood at ₹3.11 crore, lower than ₹4.24 crore reported in the comparable period. The company’s Q3 recovery therefore came within a nine-month period that still showed year-on-year pressure on revenue and profits.

Exceptional item in Q3 tied to Social Security Code costs

National Peroxide reported an exceptional item of ₹0.58 crore in Q3 FY2026. The company attributed this to actuarial valuation of past service costs for employee benefits under the newly implemented Social Security Code. Total comprehensive income for the quarter was ₹2.51 crore compared with a loss of ₹1.59 crore in the previous year’s quarter. The disclosure highlighted that the exceptional item was tied to employee benefit accounting rather than operating revenue.

Corporate governance changes: Company Secretary appointment

Alongside the Q3 results approved on February 5, 2026, the Board approved the appointment of Mr. Akshay Satasiya as Company Secretary and Compliance Officer, designated as key managerial personnel. His appointment was disclosed as effective March 9, 2026. The company noted he is an Associate Member of the Institute of Company Secretaries of India (ACS: 47389) with more than 10 years of experience in secretarial, compliance, and corporate governance functions.

Finance leadership: interim CFO to planned transition

National Peroxide appointed Mr. Amit Goriwale as Interim CFO and Interim CRO effective December 18, 2025. The company described him as a Chartered Accountant with over six years of experience across finance, accounting, audit, and taxation, and stated he was then serving as Deputy Manager (Accounts and Finance). Later, National Peroxide disclosed that Mr. Goriwale stepped down as Interim CFO and Interim CRO effective May 31, 2026. The company also stated that Mr. Chirag Kothari was appointed as CFO and CRO effective June 1, 2026, and that Mr. Goriwale would continue with the company in another role.

Earlier FY2025 pressure: rating action and weaker financials

Separately, the company faced a credit rating action after a weak FY2025. India Ratings downgraded National Peroxide’s bank loan facilities from ‘IND A’ to ‘IND A-’ with a Negative Outlook, citing pressure in operating performance. The disclosure noted revenue declined 14% year-on-year to INR 2,869 million in FY25 (₹286.90 crore), while EBITDA fell 50% to INR 152 million (₹15.20 crore). This context helps explain why FY2026’s return to profit and the resumption of a proposed dividend were notable developments for investors tracking the company’s recovery.

Key figures and dates at a glance

Market-relevant metrics disclosed

The company also disclosed an operating margin of 5.30183983212143% for the current financial year. It further stated that the current year dividend was Rs 0 and the dividend yield was 0%, reflecting that dividend distribution is tied to board recommendation and shareholder approval. The gap between a recommended dividend and the “current year dividend” metric can occur depending on record dates, approvals, and the time of data capture.

Conclusion

National Peroxide’s FY2026 performance marked a return to profitability, with FY total income of ₹295.68 crore and PAT of ₹11.04 crore after a loss in FY2025. The April 30, 2026 board meeting agenda covered audited results and a dividend recommendation, and the board subsequently recommended a ₹7 final dividend per share, subject to shareholder approval. Over the year, the company also reported notable governance updates, including changes in CFO and CRO roles and a new Company Secretary appointment. The next formal milestone for investors is the shareholder decision on the proposed dividend at the upcoming AGM.